Newsroom

PCG Client Availability in San Francisco, CA

6 months ago

dfsfds

PCG Client Availability in San Francisco, CA
January 9 – 12, 2017

To Schedule 1×1 Management Meetings, Please Contact:
Kirin Smith: ksmith@pcgadvisory.com – 646-863-6519
Adam Holdsworth: adamh@pcgadvisory.com – 646-862-4607

Abeona Therapeutics (NASDAQ: ABEO) $290mn Mcap, ~$75mn cash

  • Clinical stage bio-pharma company developing gene and plasma-based therapies for life-threatening rare genetic diseases
  • Lead programs are adeno-associated virus based gene therapies for Sanfilippo syndrome. Other programs include for recessive dystrophic epidermolysis bullosa, juvenile Batten disease, Fanconi anemia disorder
  • For more information, visit www.abeonatherapeutics.com

 

Actinium Pharmaceuticals (NYSE: ATNM) $57mn Mcap, ~$16mn cash

  • Bio-pharma company with proprietary platform that utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells
  • Lead programs product candidate for hematopoietic stem cell transplant. Ongoing pivotal Phase 3 clinical trial for R/R AML. Second product on Phase 2 for newly diagnosed AML
  • For more information, visit www.actiniumpharma.com

 

Arch Therapeutics (OTC: ARTH) $81mn Mcap, ~$6mn cash

  • Device company with novel approach to stop bleeding and control leaking during surgery and trauma care
  • Products under development leverage innovative self-assembling peptide technology
  • For more information, visit www.archtherapeutics.com

 

Asterias Biotherapeutics (NASDAQ: AST) $260mn Mcap, ~$34mn cash

  • Clinical stage immunotherapy and pluripotent stem cell platform programs in the fields of neurology and oncology
  • Phase 1/2a dose escalation in spinal cord injury; Phase 2 in AML; partnered Phase 1/2a in non-small cell lung cancer
  • For more information, visit www.asteriasbiotherapeutics.com

 

Aytu Bioscience (OTC: AYTU) $12mn Mcap, ~$11mn cash

  • Commercial-stage specialty pharma company with portfolio of novel urology products.
  • Revenue generating products include Natesto, the only-FDA approved nasel spray for low testosterone, an imaging specific PSMA for prostate cancer detection/staging, and a trimethoprim-only oral solution for urinary tract infections. Ongoing 510k clinical trial for a semen analysis system for male infertility caused by oxidative stress; product is commercial outside the US.
  • For more information, visit www.aytubio.com

 

BioLineRx (NASDAQ, TASE: BLRX) $60mn Mcap, ~$39mn cash

  • Clinical stage bio-pharma company dedicated to identifying, in-licensing and developing promising therapeutics
  • Immuno-oncology collaboration with Merck for pancreatic cancer and Genentech for pancreatic cancer, gastric cancer, non-small cell lung, maintenance AML. Three announced projects via Novartis collaboration for liver diseases/NASH/ESLD and dry eye syndrome. Commercial in Europe with OTC skin lesion product with Perrigo.
  • For more information, visit www.biolinerx.com

 

Catalyst Biosciences (NASDAQ: CBIO) $10mn Mcap, ~$49mn cash

  • Clinical stage bio-pharma company developing novel therapies for hematology indications
  • Next-gen coagulation Factor VIIa variant, marzeptacog alfa, completed intravenous Phase 1 clinical trial for severe hemophilia A or B
  • In advanced pre-clinical development for next-gen Factor IX variant
  • For more information, visit www.catalystbiosciences.com

 

Cellectar Biosciences (NASDAQ: CLRB) $12mn Mcap, ~$10mn cash

  • Developing phospholipid drug conjugates for targeted cancer delivery of diverse oncologic payloads
  • Lead therapeutic utilizing iodine-131 as payload currently in orphan designated Phase 1 clinical trial for R/R multiple myeloma
  • Pipeline includes paclitaxel
  • For more information, visit www.celectar.com

 

Check-Cap (NASDAQ: CHEK) $31mn Mcap, ~$13mn cash

  • Clinical-stage medical diagnostic company developing low dose x-ray based ingestible capsule for preparation free, minimally invasive colorectal cancer screening
  • Designed to increase willingness to participate in screening, addresses barriers such as laxative bowel preparation, invasiveness, sedation
  • For more information, visit www.check-cap.com

 

Champions Oncology (NASDAQ: CSBR) $20mn Mcap, ~$4mn cash

  • Developing TumorGraft technology platform to personalize cancer care based on implantation of primary human tumors in immune deficient mice to determine efficacy of drug/treatment regimen
  • Targeting two groups: Personalized Oncology Solutions and Translational Oncology Solutions for pharma/biotech companies
  • For more information, visit www.championsoncology.com

 

Cytori Therapeutics (NASDAQ: CYTX) $34mn Mcap, ~$15mn cash

  • Late stage cell therapy company developing autologous cell therapies from adipose tissue to treat variety of medical conditions
  • Three ongoing Phase 3 clinical trials: scleroderma hand disease in US and Europe and urinary incontinence in Japan
  • For more information, visit www.cytori.com

 

Enumeral Biomedical Holdings (OTC-ENUM) ~$10mn Mcap

  • Bio-pharma company focused on discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells
  • Unique platform allows for to identifying and characterizing promising new drugs relevant to cancer, infectious and inflammatory diseases
  • Developing two antagonist PD-1 antibodies, ENUM 388D4 and ENUM 288C4 for use in treating cancer
  • For more information, please visit: www.enumeral.com

 

Inovio Pharmacueticals (NASDAQ: INO) $581mn Mcap, ~$120mn cash

  • DNA-based immunotherapy platform; advancing multiple cancer and infectious disease products
  • Lead product focused on cervical high-grade pre-cancer caused by HPV
  • Expanding portfolio of immune therapies; advancing pre-clinical and clinical pipeline; In collaboration with MedImmune, DARPA, UPenn, NCI, among others
  • For more information, visit www.inovio.com

 

Intellipharmaceutics Int’l (NASDAQ: IPCI) $90mn Mcap, ~$4mn cash

  • Specialty-Pharma company specializing in novel and generic controlled-release and targeted-release oral solid dosage drugs
  • Leveraging patented Hypermatrix technology, a multidimensional controlled-release delivery platform. Basket of FDA approved drugs and candidates in development
  • For more information, visit www.intellipharmaceutics.com

 

IsoRay (NYSE: ISR) $32mn Mcap, ~$14mn cash

  • Sole producer of Cesium-131 brachytherapy seeds; expanding brachytherapy options throughout the body
  • New management team has intense focus on driving revenue growth
  • For more information, visit www.isoray.com

 

MannKind Corporation (NASDAQ: MKND) $290mn Mcap, ~$35.5mn in cash

  • Focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes
  • Launching Afrezza®, a disruptive technology for the treatment of diabetes using powdered insulin
  • Technosphere ® Clinical pipeline with 3 technologies; Epinephrine, Trepostinil, & Palonestron
  • For more information, please visit: www.mannkindcorp.com

 

Myomo (Private)

  • Myomo, Inc., is a medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions such as brachial plexus injury, traumatic brain injury, spinal cord injury, multiple sclerosis, ALS, and stroke.
  • The Company’s myoelectric orthoses have been clinically shown to help restore the ability to complete functional tasks by enabling individuals to self-initiate and control movement of their partially paralyzed limbs by using their own muscle signals.
  • The Myomo technology was originally developed at Massachusetts Institute of Technology in collaboration with medical experts affiliated with Harvard Medical School. Myomo, Inc. is a privately held company headquartered in Cambridge, MA.
  • For more infiormaiton, please visit: www.myomo.com

 

Moleculin Biotech (NASDAQ: MBRX) $33mn Mcap, ~$6mn cash

  • Pre-clinical and clinical stage pharma company developing anti-cancer drugs, some of which are based on discoveries of MD Anderson Cancer Center
  • Ongoing Phase II clinical trial for R/R AML. Two pre-clinical small molecule portfolios: 1) modulation of hard to target tumor cell signaling mechanisms and recruitment of patient’s own immune system and 2) targeting of tumor metabolism
  • For more information, visit www.moleculin.com

 

Nemus Bioscience (OTC: NMUS) $10mn Mcap

  • Bio-pharma company developing cannabinoid-based therapeutics, utilizing proprietary tech from U of MS, for specific indications, including ocular applications
  • For more information, visit www.nemusbioscience.com

 

Nephros (OTC: NEPH) $20mn Mcap

  • A commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease
  • For more information, visit www.nephros.com

 

Onconova Therapeutics (NASDAQ: ONTX) $21mn Mcap, ~$26mn cash

  • Phase 3 clinical-stage bio-pharma company with novel products to treat cancer
  • Most advanced product candidate, rigosertib, is a small molecular inhibitor of cellular signaling/RAS mimetic – awarded orphan designation for myelodysplastic syndrome
  • For more information, visit www.onconova.com

 

PixarBio Corporation (OTC: PXRB) $440mn Mcap, ~$7mn cash

  • Spec pharma/biotech company focused on novel neurological drug delivery systems for post-operative pain, epilepsy, Parkinson’s Disease, spinal cord injury
  • Lead product reports sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain in pre-clinical studies
  • For more information, visit www.pixarbio.com

 

Xenetic Biosciences (OTC: XBIO) $28mn Mcap, ~$9mn cash

  • Clinical stage bio-pharma company focused on next-gen biologics and novel oncology therapeutics
  • Lead product candidates include polysialylated form of erythropoietin for anemia in pre-dialysis patients, orphan designated oncology therapeutics, and progesterone receptor negative endometrial cancer, as well as refractory AML. In partnership with Shire for novel series of polysialylated blood coagulant factors
  • For more information, visit www.xeneticbio.com

 


To Schedule a 1×1 Management Meeting, Contact:
PCG Advisory Group
Kirin Smith  ksmith@pcgadvisory.com – 646-863-6519
Adam Holdsworth  adamh@pcgadvisory.com – 646-862-4602

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address